4 CHAPTER 4 90 References 1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. 2. Louter MA, Pijpers JA, Wardenaar KJ, et al. Symptom dimensions of affective disorders in migraine patients. J Psychosom Res. 2015;79(5):458-463. 3. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology. 2003;60(8):1308-1312. 4. Hillard CJ, Beatka M, Sarvaideo J. Endocannabinoid Signaling and the Hypothalamic-Pituitary-Adrenal Axis. Compr Physiol. 2016;7(1):1-15. 5. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res. 2009;60(2):85-92. 6. Szabo B, Schlicker E. Effects of Cannabinoids on Neurotransmission. In: Pertwee RG, ed. Cannabinoids. Springer Berlin Heidelberg; 2005:327-365. 7. Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622. 8. Bruno PP, Carpino F, Carpino G, Zicari A. An overview on immune system and migraine. Eur Rev Med Pharmacol Sci. 2007;11(4):245-248. 9. AkermanS,KaubeH,GoadsbyPJ.Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascularmediated nociception. J Pharmacol Exp Ther. 2004;309(1):56-63. 10. Akerman S, Holland PR, Goadsby PJ. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther. 2007;320(1):64-71. 11. Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018;19(3):833. 12. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002;6869:619-631. 13. Ross RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol. 2003;140(5):790801. 14. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400(6743):452-457. 15. Engel MA, Izydorczyk I, Mueller-Tribbensee SM, et al. Inhibitory CB1 and activating/ desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin. Neuropeptides. 2011;45(3):229-237. 16. Sugiura T, Kondo S, Kishimoto S, et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL60 cells. J Biol Chem. 2000;275(1):605-612. 17. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008;14(9):923930. 18. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 2001;29(3):729738. 19. Rea K, Roche M, Finn DP. Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol. 2007;152(5):633-648. 20. Sarchielli P, Pini LA, Coppola F, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007;32(6):13841390. 21. Greco R, Gasperi V, Sandrini G, et al. Alterations of the endocannabinoid system in an animal model of migraine: evaluation in cerebral areas of rat. Cephalalgia. 2010;30(3):296-302.
RkJQdWJsaXNoZXIy MTk4NDMw